ABL503 (TJ-L14B), PD-L1X4-1BB BISPECIFIC ANTIBODY INDUCES SUPERIOR ANTI-TUMOR ACTIVITY BY PD-L1-DEPENDENT 4-1BB ACTIVATION WITH THE INCREASE OF 4-1BB+CD8+T CELLS IN TUMOR MICROENVIRONMENT

被引：0
|
作者：
Jung, Uijung [1 ]
Jeon, Jaehyoung [1 ]
Lee, Shinai [1 ]
Jin, Hyung-Seung [2 ]
Kim, Youngkwang [1 ]
Sung, Eunsil [1 ]
Kim, Hyunjoo [1 ]
Lim, Yangmi [1 ]
Won, Jonghwa [1 ]
Wang, Zhengyi [3 ]
Jiang, Wenqing [3 ]
Jung, Jaeho [1 ]
You, Gihoon [1 ]
机构：
[1] ABL Bio Inc, Seongnam, South Korea
[2] Asan Med Ctr, Seoul, South Korea
[3] I Mab Biopharma, Shanghai, Peoples R China
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2021年 / 9卷
关键词：
D O I：
10.1136/jitc-2021-SITC2021.892
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
892
引用
收藏
页码：A935 / A935
页数：1
相关论文
共 50 条
  • [41] Assessment of target-mediated biodistribution of an 89Zr labeled PD-L1/4-1BB bispecific Mabcalin protein
    van Winkel, Claudia A.
    Fan, Xiaoyu
    Giesen, Danique
    Gauderat, Glenn
    Pattarini, Lucia
    Jaquin, Thomas
    Barakat, Anissa
    De La Bigne, Anne-Marie
    Richter, Marleen
    Andersen, Nicole
    Legrand, Julie
    Lelievre, Helene
    de Vries, Elisabeth G.
    Morales-Kastresana, Aizea
    Lub-de Hooge, Marjolijn N.
    CANCER RESEARCH, 2023, 83 (07)
  • [42] HBM7008, A FIRST-IN-CLASS BISPECIFIC ANTIBODY TARGETING BOTH B7-H4 AND 4-1BB, EXHIBITS ROBUST ANTI-TUMOR IMMUNITY AND LOW TOXICITY THROUGH B7-H4-DIRECTED 4-1BB ACTIVATION
    Huang, Bing
    Du, Fangfang
    Lv, Xiaocheng
    Zhao, Jianxun
    Chen, Fei
    Lu, Zailian
    Zhang, Yang
    Chen, Victor
    Gan, Xin
    Zhao, Jiuqiao
    He, Yun
    Wu, Xiaodong
    Rong, Yiping
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A1099 - A1099
  • [43] DUAL-TARGETING OF 4-1BB AND OX40 WITH AN ADAPTIR™ BISPECIFIC ANTIBODY ENHANCES ANTI-TUMOR RESPONSES TO SOLID TUMOR
    Nelson, Michelle
    Miller, Robert
    Blahnik-Fagan, Gabriele
    Loh, Lauren
    Van Citters, Danielle
    Misher, Lynda
    Sprague, Megan
    Dasovich, Maria
    Barber, Irene
    Maggiora, Kathy
    Gruswitz, Franz
    Woodruff, Brian
    Huntington, Kelsey
    Guinn, Aelish
    Aguilar, Megan
    Daugherty, Mollie
    Haglin, Elizabeth
    Gross, Jane
    Pavlik, Peter
    McMahan, Catherine
    Bienvenue, David
    Hernandez-Hoyos, Gabriela
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A379 - A380
  • [44] A phase I/IIa first-in-human study of PM1003 (anti-PD-L1 x 4-1BB bispecific antibody) in patients with advanced solid tumors
    Xue, J.
    Sun, Y.
    Li, D.
    Guo, Y.
    ANNALS OF ONCOLOGY, 2023, 34 : S629 - S629
  • [45] PERIPHERAL AND TUMORAL IMMUNE ACTIVITY IN THE EXPANSION PART OF THE FIRST-IN-HUMAN DUOBODY®-PD-L1x4-1BB (GEN1046) TRIAL
    Ponce Aix, Santiago
    Calvo, Emiliano
    Moreno, Victor
    Garralda, Elena
    Cervantes, Andres
    Ramalingam, Suresh
    Perez, Jose Trigo
    LoRusso, Patricia
    Furqan, Muhammad
    Cho, Daniel
    Muik, Alexander
    Lagkadinou, Eleni
    Tureci, Ozlem
    Couto, Suzana
    Pencheva, Nora
    Forssmann, Ulf
    Sahin, Ugur
    Ahmadi, Tahamtan
    Higgs, Brandon
    Jure-Kunkel, Maria
    Melero, Ignacio
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A546 - A546
  • [46] Combination of 4-1BB Agonist and PD-1 Antagonist Promotes Antitumor Effector/Memory CD8 T Cells in a Poorly Immunogenic Tumor Model
    Chen, Shihao
    Lee, Li-Fen
    Fisher, Timothy S.
    Jessen, Bart
    Elliott, Mark
    Evering, Winston
    Logronio, Kathryn
    Tu, Guang Huan
    Tsaparikos, Konstantinos
    Li, Xiaoai
    Wang, Hui
    Ying, Chi
    Xiong, Mengli
    VanArsdale, Todd
    Lin, John C.
    CANCER IMMUNOLOGY RESEARCH, 2015, 3 (02) : 149 - 160
  • [47] Phase I safety and preliminary efficacy of PM1003, a bispecific antibody targeting PD-L1 and 4-1BB, in patients with advanced solid tumors
    Xue, Junli
    Sun, Yuping
    Li, DaPeng
    Guo, Ye
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [48] A COMPUTATIONAL SEMI-MECHANISTIC PHARMACOLOGY MODEL OF ATG101, A PD-L1/4-1BB BISPECIFIC ANTIBODY FOR TREATMENT OF SOLID TUMORS AND NHL
    Flowers, David
    Presler, Marc
    Subramanian, Kas
    Yuraszeck, Theresa
    Hui Yuwen
    Hou, Bing
    Hoenemann, Dirk
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A241 - A242
  • [49] A BIPARATOPIC ANTI-HER2 ANTIBODY ENABLED WITH CONDITIONAL 4-1BB AGONISM INDUCES POTENT ANTI-TUMOR EFFICACY
    Chen, Liandi
    Huang, Weifeng
    Miao, Xiaoniu
    Peng, Shaogang
    Wang, Chao
    Yan, Yao
    Chou, Chuan-Chu
    Tsun, Andy
    Luo, Yi
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A1372 - A1372
  • [50] Combination antibody treatment targeting PD-L1 and 4-1BB leads to reduced anti-tumor immunity against CT26 tumors in B-cell deficient JH-/- mice
    Yan, Zhengming
    Llewellyn, Heather
    Kelleher, Kerry
    Pascual, Bernadette
    Stauffer, Angela
    Ding, Ying
    Li, Xiaorong
    Ozeck, Mark
    Toste, Jeffrey
    Yang, Han
    Zhang, Haikuo
    Ram, Sripad
    Zhang, Cathy
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
12345